Wockhardt has received its board’s approval to raise up to Rs 2200 crore through equity and debt instruments. The company has decided to raise up to Rs 1200 crore through issuance of non-convertible debentures (NCDs) on a private placement basis and up to Rs 1000 crore through equity instruments, including qualified institutional placement (QIP) of shares.
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
